ֱ

GLP-1 Drugs Tame Brain Inflammation; Novel Painkiller Succeeds; Headache as Metaphor

— News and commentary from the world of neurology and neuroscienc

MedpageToday
Neuro Break over a computer rendering of neurons.

Glucagon-like peptide 1 (GLP-1) receptor agonists that reduce obesity also , leading researchers to investigate how these agents might help treat Alzheimer's or Parkinson's disease. (Nature)

IV compared with IV morphine in reducing out-of-hospital traumatic pain, the KETAMORPH trial showed. (JAMA Network Open)

VX-548, an investigational selective NaV1.8 inhibitor, in phase III trials, Vertex Pharmaceuticals announced.

Memory clinic patients had than historical controls during the COVID-19 lockdown in the Netherlands. (Alzheimer's & Dementia)

Takeda's (Gammagard liquid) was approved as an IV therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), the company said.

The first person in Neuralink's PRIME trial had a , according to the company's founder, Elon Musk. (Reuters)

The Montreal Cognitive Assessment identified people with isolated REM sleep behavior disorder who were most at risk of developing . (Neurology)

Electroencephalography (EEG) microstate analysis identified different and focal epilepsy. (Epilepsia)

Researchers outlined strategies to in neurology translational research. (Annals of Neurology)

A random sample of 1,000 sentences with the showed the term was used metaphorically half the time, which may trivialize headache disorders. (Headache)

How to treat central nervous system (CNS) disorders? (JAMA Neurology)

  • Judy George covers neurology and neuroscience news for ֱ, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.